论文部分内容阅读
目的检测趋化因子CXCL12及其受体CXCR4在子宫内膜癌组织中的表达水平,探讨其与子宫内膜癌患者的临床病理特征和预后的关系。方法采用组织芯片技术和免疫组化方法检测子宫内膜癌组织中CXCL12、CXCR4表达水平,并分析它们与FIGO分期、细胞分化程度、淋巴结转移、病理类型及年龄等临床病理特征及总生存率的关系。结果子宫内膜癌组织中CXCL12、CXCR4的表达水平均显著高于正常子宫内膜组,且二者在子宫内膜癌组的上调表达呈正相关。CXCR4的表达与子宫内膜癌细胞分化程度呈正相关(P<0.05)。CXCL12、CXCR4均不影响子宫内膜癌患者的生存率(P>0.05)。结论 CXCL12和CXCR4可能在子宫内膜癌的发生、发展中发挥生物学作用。
Objective To investigate the expression of chemokine CXCL12 and its receptor CXCR4 in endometrial carcinoma and its relationship with the clinicopathological features and prognosis of patients with endometrial carcinoma. Methods The expression of CXCL12 and CXCR4 in endometrial carcinoma was detected by tissue microarray and immunohistochemistry, and their clinicopathological features and the overall survival rate (FIGO stage, cell differentiation, lymph node metastasis, pathological type and age) were analyzed relationship. Results The expression levels of CXCL12 and CXCR4 in endometrial carcinoma were significantly higher than those in normal endometrium, and the expression of CXCL12 and CXCR4 in endometrial carcinoma was positively correlated. The expression of CXCR4 was positively correlated with the degree of differentiation of endometrial carcinoma cells (P <0.05). CXCL12 and CXCR4 did not affect the survival rate of patients with endometrial cancer (P> 0.05). Conclusion CXCL12 and CXCR4 may play a biological role in the development of endometrial carcinoma.